Takeda Pharmaceutical Company Limited (FRA:TKD)

Market Cap	39.45B
Revenue (ttm)	26.44B
Net Income (ttm)	808.10M
Shares Out	n/a
EPS (ttm)	0.50
PE Ratio	48.82
Forward PE	n/a
Dividend	1.21 (4.92%)
Ex-Dividend Date	Mar 28, 2025

Volume	416
Average Volume	496
Open	25.04
Previous Close	25.04
Day's Range	24.97 - 25.04
52-Week Range	23.54 - 28.29
Beta	n/a
RSI	54.24
Earnings Date	Jul 30, 2025

About FRA:TKD

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, A...

• Industry: Pharmaceutical Preparations
• Founded: 1781
• Employees: 47,455
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: TKD

Financial Performance

In 2024, FRA:TKD's revenue was 4.58 trillion, an increase of 7.45% compared to the previous year's 4.26 trillion. Earnings were 107.93 billion, a decrease of -25.08%.

Financial numbers in JPY